DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
von Minckwitz G, Bear H, Bonnefoi H. et al.
Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptorpositive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13).
Cancer Res 2013;
DOI: 10.1158/0008-5472.SABCS13-OT2-6-11.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.